We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
(-13%)
Cap. Flow
-$196M
Cap. Flow
% of AUM
-6.55%
Top 10 Holdings %
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15
Avg Time Held Equity + Options
8.8
quarters
Top 10 Avg Time Held Equity + Options
5.7
quarters
Top 20 Avg Time Held Equity + Options
5.8
quarters
Avg Time Held Equity only
9.8
quarters
Top 10 Avg Time Held Equity only
5.7
quarters
Top 20 Avg Time Held Equity only
5.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$40.3M |
| 2 |
argenx
ARGX
|
+$39.9M |
| 3 |
Revolution Medicines
RVMD
|
+$39.2M |
| 4 |
Immunovant
IMVT
|
+$29.2M |
| 5 |
RayzeBio, Inc. Common Stock
RYZB
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$68.3M |
| 2 |
Vir Biotechnology
VIR
|
+$48M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$46.2M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$35.7M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$33.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.21% |
| 2 | Miscellaneous | 0.79% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
DELISTED
Astria Therapeutics
ATXS
| $16.3M | 0.54% |
2,189,462
| – | – |
2021 Q1
10 quarters
|
|
52
Viridian Therapeutics
VRDN
$2.06B
| $15.5M | 0.52% |
1,011,205
-765,181
| -43% | -$14.6M |
2021 Q2
9 quarters
|
|
53
Artivion
AORT
$1.04B
| $14.1M | 0.47% |
931,352
| – | – |
2021 Q4
7 quarters
|
|
54
Establishment Labs
ESTA
$1.74B
| $13.6M | 0.45% |
277,683
-147,241
| -35% | -$8.8M |
2018 Q3
20 quarters
|
|
55
Evolus
EOLS
$496M
| $13.6M | 0.45% |
+1,485,801
| New | +$13.3M |
2023 Q3
0 quarters
|
|
56
Tactile Systems Technology
TCMD
$505M
| $9.94M | 0.33% |
707,159
+104,782
| +17% | +$2.05M |
2023 Q1
2 quarters
|
|
57
Biomea Fusion
BMEA
$91.3M
| $9.86M | 0.33% |
716,441
| – | – |
2023 Q1
2 quarters
|
|
58
LeonaBio Inc
LONA
$60.6M
| $9.69M | 0.32% |
479,728
| – | – |
2020 Q3
12 quarters
|
|
59
Natera
NTRA
$57B
| $9.65M | 0.32% |
218,178
-187,091
| -46% | -$9.54M |
2022 Q3
4 quarters
|
|
60
Zymeworks
ZYME
$1.8B
| $9.17M | 0.31% |
1,446,123
-970,109
| -40% | -$7.16M |
2017 Q2
25 quarters
|
|
61
Solid Biosciences
SLDB
$624M
| $8.81M | 0.29% |
3,495,933
| – | – |
2020 Q2
13 quarters
|
|
62
Rhythm Pharmaceuticals
RYTM
$5.96B
| $8.73M | 0.29% |
+380,828
| New | +$8.53M |
2023 Q3
0 quarters
|
|
63
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $8.11M | 0.27% |
127,452
+205
| +0.2% | +$14.4K |
2020 Q4
11 quarters
|
|
64
Prothena Corp
PRTA
$429M
| $7.99M | 0.27% |
165,615
-19,000
| -10% | -$1.13M |
2022 Q3
4 quarters
|
|
65
Outset Medical
OM
$76.3M
| $7.2M | 0.24% |
44,132
-16,025
| -27% | -$3.78M |
2020 Q3
12 quarters
|
|
66
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $7.15M | 0.24% |
2,751,395
| – | – |
2023 Q1
2 quarters
|
|
67
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| $5.77M | 0.19% |
1,486,991
| – | – |
2021 Q1
10 quarters
|
|
68
CALL
DELISTED
Akero Therapeutics
AKRO
| $5.46M | 0.18% |
+800,000
| New | +$37.2M |
2023 Q3
0 quarters
|
|
69
DELISTED
Terns Pharmaceuticals
TERN
| $5.41M | 0.18% |
+1,075,000
| New | +$6.82M |
2023 Q3
0 quarters
|
|
70
Tyra Biosciences
TYRA
$1.28B
| $4.96M | 0.17% |
360,000
| – | – |
2021 Q3
8 quarters
|
|
71
Nanobiotix
NBTX
$1.09B
| $4.86M | 0.16% |
555,066
-504,734
| -48% | -$4.19M |
2020 Q4
11 quarters
|
|
72
Axogen
AXGN
$2.12B
| $4.38M | 0.15% |
875,898
-588,924
| -40% | -$4.08M |
2022 Q3
4 quarters
|
|
73
enVVeno Medical
NVNO
$5.54M
| $4.21M | 0.14% |
22,332
| – | – |
2021 Q4
7 quarters
|
|
74
X4 Pharmaceuticals
XFOR
$258M
| $3.86M | 0.13% |
118,182
| – | – |
2023 Q1
2 quarters
|
|
75
PUT
Novavax
NVAX
$2.11B
| $3.77M | 0.13% |
+1,300,000
| New | +$10.4M |
2023 Q3
0 quarters
|
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $196M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.
- Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
- Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
- Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
- Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
- Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
- Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.
Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.